CN104622902A - 一种用于治疗肝纤维化的干细胞制剂 - Google Patents
一种用于治疗肝纤维化的干细胞制剂 Download PDFInfo
- Publication number
- CN104622902A CN104622902A CN201510024090.2A CN201510024090A CN104622902A CN 104622902 A CN104622902 A CN 104622902A CN 201510024090 A CN201510024090 A CN 201510024090A CN 104622902 A CN104622902 A CN 104622902A
- Authority
- CN
- China
- Prior art keywords
- stem cell
- cell
- hepatic fibrosis
- treatment
- culture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 56
- 206010019668 Hepatic fibrosis Diseases 0.000 title claims abstract description 34
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 9
- 210000004369 blood Anatomy 0.000 claims abstract description 9
- 239000008280 blood Substances 0.000 claims abstract description 9
- 210000004027 cell Anatomy 0.000 claims description 40
- 210000004914 menses Anatomy 0.000 claims description 29
- 239000003814 drug Substances 0.000 claims description 15
- 238000002347 injection Methods 0.000 claims description 13
- 239000007924 injection Substances 0.000 claims description 13
- 102000019034 Chemokines Human genes 0.000 claims description 12
- 108010012236 Chemokines Proteins 0.000 claims description 12
- 239000001963 growth medium Substances 0.000 claims description 10
- 210000005087 mononuclear cell Anatomy 0.000 claims description 8
- 239000012930 cell culture fluid Substances 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 6
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 claims description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 5
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 claims description 5
- 229960003942 amphotericin b Drugs 0.000 claims description 5
- 238000001514 detection method Methods 0.000 claims description 5
- 230000009977 dual effect Effects 0.000 claims description 5
- 230000014509 gene expression Effects 0.000 claims description 5
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 238000000926 separation method Methods 0.000 claims description 5
- 238000004113 cell culture Methods 0.000 claims description 4
- 230000003442 weekly effect Effects 0.000 claims description 4
- 102100022464 5'-nucleotidase Human genes 0.000 claims description 3
- 102100032912 CD44 antigen Human genes 0.000 claims description 3
- 208000035473 Communicable disease Diseases 0.000 claims description 3
- 229920001917 Ficoll Polymers 0.000 claims description 3
- 102000006354 HLA-DR Antigens Human genes 0.000 claims description 3
- 108010058597 HLA-DR Antigens Proteins 0.000 claims description 3
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 3
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 claims description 3
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims description 3
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 3
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 claims description 3
- 101001008874 Homo sapiens Mast/stem cell growth factor receptor Kit Proteins 0.000 claims description 3
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 3
- 102100025304 Integrin beta-1 Human genes 0.000 claims description 3
- 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 claims description 3
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 3
- 230000001464 adherent effect Effects 0.000 claims description 3
- 238000000432 density-gradient centrifugation Methods 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims description 3
- 230000002906 microbiologic effect Effects 0.000 claims description 3
- 244000052769 pathogen Species 0.000 claims description 3
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 claims description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 2
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 claims description 2
- 230000001413 cellular effect Effects 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 abstract description 9
- 238000000034 method Methods 0.000 abstract description 6
- 230000002175 menstrual effect Effects 0.000 abstract description 5
- 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 abstract description 3
- 102100026236 Interleukin-8 Human genes 0.000 abstract description 3
- 230000004069 differentiation Effects 0.000 abstract description 3
- 238000001802 infusion Methods 0.000 abstract description 3
- 230000003833 cell viability Effects 0.000 abstract description 2
- 230000035755 proliferation Effects 0.000 abstract description 2
- 239000005482 chemotactic factor Substances 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 9
- 238000002054 transplantation Methods 0.000 description 9
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 7
- 208000019425 cirrhosis of liver Diseases 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 210000003494 hepatocyte Anatomy 0.000 description 6
- 210000005228 liver tissue Anatomy 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 230000002440 hepatic effect Effects 0.000 description 4
- 208000019423 liver disease Diseases 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000000378 dietary effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 108010017314 prolyl dipeptidase Proteins 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000011476 stem cell transplantation Methods 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000035605 chemotaxis Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 238000000151 deposition Methods 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 210000000963 osteoblast Anatomy 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 208000037816 tissue injury Diseases 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010057573 Chronic hepatic failure Diseases 0.000 description 1
- 102000002734 Collagen Type VI Human genes 0.000 description 1
- 108010043741 Collagen Type VI Proteins 0.000 description 1
- 208000010334 End Stage Liver Disease Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 206010041047 Slow virus infection Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 210000004504 adult stem cell Anatomy 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 208000011444 chronic liver failure Diseases 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000007646 directional migration Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 230000009795 fibrotic process Effects 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 210000004024 hepatic stellate cell Anatomy 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- -1 lipid peroxide Chemical class 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 238000007449 liver function test Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000000651 myofibroblast Anatomy 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 238000000879 optical micrograph Methods 0.000 description 1
- 210000004738 parenchymal cell Anatomy 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510024090.2A CN104622902B (zh) | 2015-01-17 | 2015-01-17 | 一种用于治疗肝纤维化的干细胞制剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510024090.2A CN104622902B (zh) | 2015-01-17 | 2015-01-17 | 一种用于治疗肝纤维化的干细胞制剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104622902A true CN104622902A (zh) | 2015-05-20 |
CN104622902B CN104622902B (zh) | 2019-01-01 |
Family
ID=53202464
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510024090.2A Active CN104622902B (zh) | 2015-01-17 | 2015-01-17 | 一种用于治疗肝纤维化的干细胞制剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104622902B (zh) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105861439A (zh) * | 2016-04-21 | 2016-08-17 | 浙江生创精准医疗科技有限公司 | 细胞组合物和用于治疗急性肺损伤的经血间充质干细胞药物及其用途 |
CN105920585A (zh) * | 2016-06-13 | 2016-09-07 | 浙江生创精准医疗科技有限公司 | Mcp-1单独或与其他细胞因子联合在治疗肝纤维化中的用途 |
CN106236776A (zh) * | 2016-08-26 | 2016-12-21 | 杭州易文赛生物技术有限公司 | 一种宫内膜干细胞在制备治疗肝脏纤维化药物中的应用 |
CN106267161A (zh) * | 2016-09-30 | 2017-01-04 | 广州赛莱拉干细胞科技股份有限公司 | 一种干细胞制剂及其制备方法和应用 |
CN109316491A (zh) * | 2018-11-05 | 2019-02-12 | 北京世纪劲得生物技术有限公司 | Nk细胞联合间充质干细胞在治疗肝炎及肝纤维化中的应用 |
CN110564679A (zh) * | 2019-06-06 | 2019-12-13 | 中国人民解放军第四军医大学 | 一种改良型间充质干细胞的制备方法及应用 |
CN110964691A (zh) * | 2019-12-31 | 2020-04-07 | 南昌诺汇医药科技有限公司 | 子宫内膜干细胞的定向成脂分化培养 |
CN111235100A (zh) * | 2020-02-21 | 2020-06-05 | 新乡医学院 | 一种人脐带血间充质干细胞的培养方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102008507A (zh) * | 2010-11-21 | 2011-04-13 | 天津和泽干细胞科技有限公司 | 人脐带间充质干细胞抗肝纤维化注射液及其制备方法 |
CN103173407A (zh) * | 2011-07-07 | 2013-06-26 | 杭州易文赛生物技术有限公司 | 利用宫内膜干细胞诱导分化肝脏细胞的方法 |
CN103305461A (zh) * | 2013-07-03 | 2013-09-18 | 顺昊细胞生物技术(天津)有限公司 | 一种以月经产物制备间充质干细胞的方法 |
CN103374760A (zh) * | 2012-04-19 | 2013-10-30 | 孙勇 | 人宫内膜(经血)干细胞库的构建 |
-
2015
- 2015-01-17 CN CN201510024090.2A patent/CN104622902B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102008507A (zh) * | 2010-11-21 | 2011-04-13 | 天津和泽干细胞科技有限公司 | 人脐带间充质干细胞抗肝纤维化注射液及其制备方法 |
CN103173407A (zh) * | 2011-07-07 | 2013-06-26 | 杭州易文赛生物技术有限公司 | 利用宫内膜干细胞诱导分化肝脏细胞的方法 |
CN103374760A (zh) * | 2012-04-19 | 2013-10-30 | 孙勇 | 人宫内膜(经血)干细胞库的构建 |
CN103305461A (zh) * | 2013-07-03 | 2013-09-18 | 顺昊细胞生物技术(天津)有限公司 | 一种以月经产物制备间充质干细胞的方法 |
Non-Patent Citations (5)
Title |
---|
JOCHEN RINGE ET AL.: ""Towards in situ tissue repair: human mesenchymal stem cells express chemokine receptors CXCR1, CXCR2 and CCR2, and migrate upon stimulation with CXCL8 but not CCL2"", 《JOURNAL OF CELLULAR BIOCHEMISTRY》 * |
余跃: "《干细胞基础与临床》", 29 February 2008, 中国科学技术大学出版社 * |
周云帆等: ""经血源性子宫内膜间充质干细胞的分离、培养与鉴定"", 《中国组织工程研究与临床康复》 * |
李兴泽等: ""趋化因子CXCL-8趋化骨髓间充质干细胞迁移的体外效应"", 《中国组织工程研究与临床康复》 * |
林建: ""宫内膜干细胞的成肝分化及其对肝损伤修复作用的研究"", 《中国优秀硕士学位论文全文数据库医药卫生科技辑》 * |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105861439A (zh) * | 2016-04-21 | 2016-08-17 | 浙江生创精准医疗科技有限公司 | 细胞组合物和用于治疗急性肺损伤的经血间充质干细胞药物及其用途 |
CN105920585A (zh) * | 2016-06-13 | 2016-09-07 | 浙江生创精准医疗科技有限公司 | Mcp-1单独或与其他细胞因子联合在治疗肝纤维化中的用途 |
CN105920585B (zh) * | 2016-06-13 | 2019-07-09 | 浙江生创精准医疗科技有限公司 | Mcp-1单独或与其他细胞因子联合在治疗肝纤维化中的用途 |
CN106236776A (zh) * | 2016-08-26 | 2016-12-21 | 杭州易文赛生物技术有限公司 | 一种宫内膜干细胞在制备治疗肝脏纤维化药物中的应用 |
CN106267161A (zh) * | 2016-09-30 | 2017-01-04 | 广州赛莱拉干细胞科技股份有限公司 | 一种干细胞制剂及其制备方法和应用 |
CN109316491A (zh) * | 2018-11-05 | 2019-02-12 | 北京世纪劲得生物技术有限公司 | Nk细胞联合间充质干细胞在治疗肝炎及肝纤维化中的应用 |
CN110564679A (zh) * | 2019-06-06 | 2019-12-13 | 中国人民解放军第四军医大学 | 一种改良型间充质干细胞的制备方法及应用 |
CN110564679B (zh) * | 2019-06-06 | 2022-09-20 | 中国人民解放军第四军医大学 | 一种改良型间充质干细胞的制备方法及应用 |
CN110964691A (zh) * | 2019-12-31 | 2020-04-07 | 南昌诺汇医药科技有限公司 | 子宫内膜干细胞的定向成脂分化培养 |
CN111235100A (zh) * | 2020-02-21 | 2020-06-05 | 新乡医学院 | 一种人脐带血间充质干细胞的培养方法 |
CN111235100B (zh) * | 2020-02-21 | 2022-04-29 | 新乡医学院 | 一种人脐带血间充质干细胞的培养方法 |
Also Published As
Publication number | Publication date |
---|---|
CN104622902B (zh) | 2019-01-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104622902A (zh) | 一种用于治疗肝纤维化的干细胞制剂 | |
CN106109496B (zh) | 人脐带间充质干细胞提取物冻干粉及制备方法 | |
CN109234229B (zh) | 从胎盘血管分离间充质干细胞的方法和所用消化酶组合物 | |
CN105861430A (zh) | 一种外泌体、外泌体的制备方法及其在制备治疗脓毒症药物或者制剂中的应用 | |
CN107028980A (zh) | 用于治疗心脏疾病的药物组合物 | |
CN105132370A (zh) | 一种临床级别脂肪干细胞的制备和储存方法 | |
CN106318904A (zh) | 间充质干细胞条件培养基用于美容品领域的用途 | |
CN108348555B (zh) | 细胞扩增方法和治疗组合物 | |
CN106265740B (zh) | 脐带间充质干细胞联合黄芪多糖在制备治疗高血糖和糖尿病肾病药物中的应用 | |
CN105970300A (zh) | 一种采用血清替代物建立人脐带间充质干细胞库的方法 | |
CN109674819B (zh) | 胎盘间充质干细胞制剂及其治疗硬化病的用途 | |
CN110157666A (zh) | 脐带间充质干细胞MSCs及其培养方法和应用 | |
CN106237313A (zh) | 一种脐带间充质干细胞注射液及其制备方法和应用 | |
CN109646458B (zh) | 使用胎盘间充质干细胞制剂治疗硬化病的方法 | |
CN106924285A (zh) | 一种胎盘间充质干细胞注射液及其制备方法和应用 | |
CN105238749A (zh) | 一种复苏骨髓间充质干细胞的方法 | |
CN106798724A (zh) | 一种骨髓间充质干细胞注射液及其制备方法和应用 | |
KR20080042761A (ko) | 렙틴을 이용한 줄기세포 증식방법 | |
CN106566803A (zh) | 一种培养液及其应用和培养脐带间充质干细胞的方法 | |
CN106754685A (zh) | 一种人脂肪间充质干细胞库的构建方法 | |
CN105647872A (zh) | 一种肝损伤靶向间充质干细胞及其制备方法与应用 | |
CN106614524B (zh) | 一种间充质干细胞的保存液以及保存方法 | |
CN109628388B (zh) | 用消化酶组合物从胎盘血管分离间充质干细胞 | |
CN106701670A (zh) | 一种增强间充质干细胞分泌生物活性因子能力及培养液中活性因子的提取方法 | |
CN109646457A (zh) | 一种脐带间充质干细胞在制备治疗急性肺损伤药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: Yuhang District, Hangzhou City, Zhejiang Province, 311121 West No. 1500 Building 1 room 223 Patentee after: Hangzhou Yiwen sectop Brand Management Co.,Ltd. Address before: The city of Hangzhou in West Zhejiang province 311121 No. 1500 Building 1 room 223 Patentee before: HANGZHOU YIWENSAIKETUO STEM CELL TECHNOLOGY RESEARCH Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20200909 Address after: Room 402, building 3, No. 1500, Wenyi West Road, Cangqian street, Yuhang District, Hangzhou City, Zhejiang Province Patentee after: HANGZHOU S-EVANS BIOSCIENCES, Ltd. Address before: Yuhang District, Hangzhou City, Zhejiang Province, 311121 West No. 1500 Building 1 room 223 Patentee before: Hangzhou Yiwen sectop Brand Management Co.,Ltd. |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A stem cell preparation for treating liver fibrosis Effective date of registration: 20231115 Granted publication date: 20190101 Pledgee: Hangzhou branch of Bank of Nanjing Co.,Ltd. Pledgor: HANGZHOU S-EVANS BIOSCIENCES, Ltd. Registration number: Y2023980065713 |